These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 17868925)

  • 1. Editorial overview: clinical utility of synergy testing for multidrug resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
    Middleton PG
    Paediatr Respir Rev; 2007 Sep; 8(3):262-3, quiz 263-4. PubMed ID: 17868925
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms.
    Aaron SD
    Paediatr Respir Rev; 2007 Sep; 8(3):256-61. PubMed ID: 17868924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'.
    Saiman L
    Paediatr Respir Rev; 2007 Sep; 8(3):249-55. PubMed ID: 17868923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Strategy of antibiotic therapy by various routes of administration in the initial colonization by Pseudomonas aeruginosa].
    Châtain P
    Rev Mal Respir; 2003 Apr; 20(2 Pt 2):S105-12. PubMed ID: 12910142
    [No Abstract]   [Full Text] [Related]  

  • 5. Outpatient intravenous medications in the management of cystic fibrosis.
    Rucker RW; Harrison GM
    Pediatrics; 1974 Sep; 54(3):358-60. PubMed ID: 4213282
    [No Abstract]   [Full Text] [Related]  

  • 6. Azlocillin with and without an aminoglycoside against respiratory tract infections in children with cystic fibrosis.
    Michalsen H; Bergan T
    Scand J Infect Dis Suppl; 1981; 29():92-7. PubMed ID: 6947408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues.
    Waters V; Ratjen F
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):807-19. PubMed ID: 17140357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antibiotic treatment of lung disease in cystic fibrosis].
    Biasini GC; Pistocchi E; Miano A
    Pediatr Med Chir; 1983; 5(4):157-60. PubMed ID: 6647075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary infection and antibiotic treatment in patients with cystic fibrosis.
    Chest; 1988 Aug; 94(2 Suppl):97S-169S. PubMed ID: 3396440
    [No Abstract]   [Full Text] [Related]  

  • 10. Respiratory tract infections in cystic fibrosis.
    Weiner DJ
    Pediatr Ann; 2002 Feb; 31(2):116-23. PubMed ID: 11862722
    [No Abstract]   [Full Text] [Related]  

  • 11. The approach to Pseudomonas aeruginosa in cystic fibrosis.
    Bendiak GN; Ratjen F
    Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Etiopathogenic and therapeutic aspects of chronic respiratory infection in cystic fibrosis].
    Caramia G; Gagliardini R; Rocchi AL; Palumbo P
    Minerva Pediatr; 1986 Jul; 38(13-14):569-78. PubMed ID: 3528799
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cystic fibrosis: current therapy. Antibiotics].
    Tamm M; Héritier F; Rappaz I; Schaad UB
    Schweiz Med Wochenschr Suppl; 2000; 122():33S-37S. PubMed ID: 12536469
    [No Abstract]   [Full Text] [Related]  

  • 14. Epidemiological investigation and glycotyping of clinical Pseudomonas aeruginosa isolates from patients with cystic fibrosis by mass spectrometry: association with multiple drug resistance.
    Altman E; Wang Z; Aaron SD; Liu X; Vandemheen KL; Ferris W; Giesbrecht T; Li J
    J Microbiol Methods; 2009 Feb; 76(2):204-8. PubMed ID: 19000720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosing and managing infection in CF.
    Ratjen F
    Paediatr Respir Rev; 2006; 7 Suppl 1():S151-3. PubMed ID: 16798546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management.
    Høiby N; Koch C
    Thorax; 1990 Nov; 45(11):881-4. PubMed ID: 2256020
    [No Abstract]   [Full Text] [Related]  

  • 17. A retrospective analysis of biofilm antibiotic susceptibility testing: a better predictor of clinical response in cystic fibrosis exacerbations.
    Keays T; Ferris W; Vandemheen KL; Chan F; Yeung SW; Mah TF; Ramotar K; Saginur R; Aaron SD
    J Cyst Fibros; 2009 Mar; 8(2):122-7. PubMed ID: 19064337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and Prospects of Targeting Bacterial Two-component Systems for Antibacterial Treatment of Cystic Fibrosis Patients.
    Velikova N; Wells JM
    Curr Drug Targets; 2017; 18(6):687-695. PubMed ID: 26853320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibacterial activity of carbapenems against clinically isolated respiratory bacterial pathogens in Japan between 2003 and 2004.
    Watanabe A; Tokue Y; Kikuchi T; Gomi K; Aoki S; Satoh T; Fujimura S
    Int J Antimicrob Agents; 2005 Nov; 26(5):420-3. PubMed ID: 16216468
    [No Abstract]   [Full Text] [Related]  

  • 20. "Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis.
    Gilligan PH; Downey DG; Elborn JS; Flume PA; Funk S; Gilpin D; Kidd TJ; McCaughan J; Millar BC; Murphy PG; Rendall JC; Tunney MM; Moore JE
    J Clin Microbiol; 2018 Sep; 56(9):. PubMed ID: 29875191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.